文献速递临床试验与 GCP流行病学与生物统计

极早产儿脑氧监测指导治疗的贝叶斯分析

Treatment guided by cerebral oximetry monitoring in extremely preterm infants: a Bayesian analysis of the SafeBoosC-III randomised clinical trial.
PubMed 文献 · Trials · 2026-04-29

SafeBoosC-III试验纳入1601例极早产儿,比较出生后72小时内脑氧监测指导治疗与常规护理。主要分析显示两组在36周矫正胎龄时死亡或严重脑损伤发生率无差异(RR 1.03,95%CI 0.90-1.18)。贝叶斯二次分析显示临床重要获益的后验概率为1.5%,临床重要伤害为19.2%。

要点

  • 脑氧监测指导治疗在极早产儿中临床重要获益概率仅1.5%
  • 临床重要伤害后验概率为19.2%,提示潜在风险信号
  • 任何获益与伤害的后验概率分别为28.7%与71.3%

核心结论

  • 极早产儿出生后72小时内脑氧监测指导治疗,对36周矫正胎龄时死亡或严重脑损伤的临床重要获益后验概率为1.5%,临床重要伤害为19.2%。

研究设计与样本

  • SafeBoosC-III随机临床试验的贝叶斯二次分析,纳入1601例极早产儿。
  • 主要分析采用弱信息先验,次要分析采用基于既往试验的证据先验。

主要发现

  • 主要分析中临床重要获益后验概率1.5%,临床重要伤害19.2%。
  • 任何获益后验概率28.7%,任何伤害后验概率71.3%。
  • 基于证据先验的次要分析与主要分析结果一致。

关键数值与推荐

  • 临床重要获益或伤害定义为相对风险低于0.90或高于1.10。
  • 任何获益或伤害定义为相对风险不等于1.0。
  • 主要分析相对风险1.03(95%CI 0.90-1.18)。

临床怎么用

  • 脑氧监测指导治疗用于极早产儿时,临床重要获益概率低而伤害概率较高,需谨慎权衡。
  • 该分析结果可为临床决策和后续研究设计提供贝叶斯概率参考。

局限性

  • 为二次贝叶斯分析,结果受先验选择影响。
  • 原文未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The SafeBoosC-III trial compared treatment guided by cerebral oximetry monitoring for the first 72 h after birth with usual care in 1601 extremely preterm infants. Incidence of death or severe brain injury at 36 weeks of postmenstrual age did not differ between the cerebral oximetry and usual care group (relative risk with cerebral oximetry, 1.03; 95% CI 0.90 to 1.18). To assess the probability of clinically important benefit or harm, we conducted secondary analyses in a Bayesian framework. METHODS: Primary analyses used a weakly informative prior assuming a wide range of effects, to assess the probability that treatment guided by cerebral oximetry monitoring carried an a priori defined clinically important benefit or harm (a relative risk below 0.90 or above 1.10) or any benefit or harm (a relative risk differing from 1.0) for death or severe brain injury. Secondary analyses used an evidence-based prior derived from relevant prior trials. RESULTS: Posterior probabilities of clinically important benefit or harm were 1.5% and 19.2%, respectively. Posterior probabilities of any benefit or harm were 28.7% and 71.3%, respectively. Probabilities derived from secondary analyses using evidence-based priors were consistent with those from the primary analysis. CONCLUSION: Treatment guided by cerebral oximetry monitoring during the first 72 h after birth in extremely preterm infants resulted in posterior probabilities of 1.5% for a clinically important benefit and 19.2% for a clinically important harm with respect to the incidence of death or severe brain injury at 36 weeks of postmenstrual age. TRIAL REGISTRATION: ClinicalTrials.gov NCT03770741. Registered on 12 July 2018.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Hansen ML, Olsen MH, Lange T, et al. Treatment guided by cerebral oximetry monitoring in extremely preterm infants: a Bayesian analysis of the SafeBoosC-III randomised clinical trial. Trials. 2026. PMID: 42050627. doi:10.1186/s13063-026-09742-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。